Shares in Novo Nordisk have fallen more than 50% – down to $66.15 from a high of around $133 – over the past 12 months as tirzepatide continued to show better clinical data than semaglutide.

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake of "market challenges".

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down. The Danish company is citing a steep decline in the company’s share price.

Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard ...

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

Novo Nordisk CEO Resigns: Lars Fruergaard Jørgensen will step down as CEO following a mutual agreement with the board, with a transition plan underway as the company searches for his successor.; ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday he will continue as CEO for a while to smooth the leadership transition.

The companies engaged in an increasingly heated war of words on Monday following the drugmaker's decision to end a ...

Shares in Novo Nordisk have fallen more than 50% – down to $66.15 from a high of around $133 – over the past 12 months as tirzepatide continued to show better clinical data than semaglutide.

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake of “market ...